CLINICAL TRIALS PROFILE FOR ABILIFY
✉ Email this page to a colleague
All Clinical Trials for ABILIFY
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00044655 ↗ | Switching Medication to Treat Schizophrenia | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 2001-07-01 | This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia. |
NCT00044655 ↗ | Switching Medication to Treat Schizophrenia | Completed | Icahn School of Medicine at Mount Sinai | Phase 4 | 2001-07-01 | This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia. |
NCT00080314 ↗ | Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode | Completed | Otsuka America Pharmaceutical | Phase 3 | 2004-01-01 | The purpose of this study is to evaluate flexible doses (5-30mg) of aripiprazole versus placebo in patients with bipolar depression. |
NCT00080314 ↗ | Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | 2004-01-01 | The purpose of this study is to evaluate flexible doses (5-30mg) of aripiprazole versus placebo in patients with bipolar depression. |
NCT00080327 ↗ | Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia | Completed | Otsuka America Pharmaceutical | Phase 4 | 2003-11-01 | A study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia |
NCT00080327 ↗ | Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 4 | 2003-11-01 | A study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia |
NCT00082199 ↗ | Study of Aripiprazole in Subjects With Alcoholism | Completed | Otsuka America Pharmaceutical | Phase 4 | 2004-04-01 | The purpose of this clinical research study is to learn whether subjects treated with aripiprazole are able to abstain from alcohol use for a greater number of days than subjects treated with placebo. The safety of using aripiprazole will also be studied. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ABILIFY
Condition Name
Clinical Trial Locations for ABILIFY
Trials by Country
Clinical Trial Progress for ABILIFY
Clinical Trial Phase
Clinical Trial Sponsors for ABILIFY
Sponsor Name